ParkinsonFranceV1, PascalFrancis, Checkpoint, bibRecord, 001573

I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease

Identifieur interne : 001573 ( PascalFrancis/Checkpoint ); précédent : 001572; suivant : 001574

I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease

Auteurs : C. Gargalidis-Moudanos [France] ; N. Pizzinat ; F. Javoy-Agid ; A. Remaury ; A. Parini

Source :

Neurochemistry international [ 0197-0186 ] ; 1997.

RBID : Pascal:97-0163497

Descripteurs français

Pascal (Inist)
- Encéphale, Récepteur imidazoline, Site fixation, Amine oxidase (flavin-containing), Activité enzymatique, Putamen, Cortex cérébral, Parkinson maladie, Homme, Récepteur imidazoline I2.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Amine oxidase (flavin-containing), Binding site, Brain (vertebrata), Cerebral cortex, Enzymatic activity, Human, Imidazoline I2 receptor, Imidazoline receptor, Parkinson disease, Putamen.

Abstract

I₂-imidazoline binding site (I₂BS) has been identified with a regulatory site located on a subpopulation of monoamine oxidase (MAO)-A and -B. Previous studies showed a modification of MAO and I₂BS in the elderly and in neurodegenerative processes such as Alzheimer's disease. In the present study. we studied the potential modification of I₂ binding sites and monoamine oxidases in Parkinson's disease. Putamen and cerebral cortex were collected from 17 normal subjects (79±12 yr) and 16 patients (76 ± 9 yr) affected by Parkinson's disease. In mitochondrial preparations, radioligand binding studies with [³H]idazoxan showed that putamen and frontal cortex express equivalent amount of I₂BS. The density and affinity of I₂BS were similar in normal subjects (putamen : B_max = 207 ± 58 fmol/mg of protein, K_d = 10.1 ± 3.4 nM; cerebral cortex: B_max = 193 ± 54 fmol/mg of protein. K_d=12.8±6.8 nM) and Parkinson's disease patients (putamen: B_max = 193 ± 60 fmol/mg of proteins K_d = 9.8 ± 4.6 nM: cerebral cortex: B_max = 199 ± 49 fmol/mg of protein, K_d = 15.9 ± 8.1 nM). The activity of total monoamine oxidase and monoamine oxidase B, measured by [¹⁴C]tyramine and ['4C]phenylethylamine oxidations respectively, were higher in putamen than in cerebral cortex. No differences have been detected in the enzyme activity between normal and pathological subjects. These data suggest that, although MAO and I₂BS may play a role in the development of Parkinson's disease, they are not altered in the chronic phase of this disease.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001764
to stream PascalFrancis, to step Curation: 001882

Links to Exploration step

Pascal:97-0163497

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">I<sub>2</sub>
-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease</title>
<author><name sortKey="Gargalidis Moudanos, C" sort="Gargalidis Moudanos, C" uniqKey="Gargalidis Moudanos C" first="C." last="Gargalidis-Moudanos">C. Gargalidis-Moudanos</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM U388, Institut Louis Bugnard, CHU Rangueil</s1>
<s2>31054, Toulouse</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM U289, CHU Pitié-Salpetrière, 47 Boulevard de l'hôpital</s1>
<s2>75013, Paris</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pizzinat, N" sort="Pizzinat, N" uniqKey="Pizzinat N" first="N." last="Pizzinat">N. Pizzinat</name>
</author>
<author><name sortKey="Javoy Agid, F" sort="Javoy Agid, F" uniqKey="Javoy Agid F" first="F." last="Javoy-Agid">F. Javoy-Agid</name>
</author>
<author><name sortKey="Remaury, A" sort="Remaury, A" uniqKey="Remaury A" first="A." last="Remaury">A. Remaury</name>
</author>
<author><name sortKey="Parini, A" sort="Parini, A" uniqKey="Parini A" first="A." last="Parini">A. Parini</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">97-0163497</idno>
<date when="1997">1997</date>
<idno type="stanalyst">PASCAL 97-0163497 INIST</idno>
<idno type="RBID">Pascal:97-0163497</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001764</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001882</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001573</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001573</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">I<sub>2</sub>
-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease</title>
<author><name sortKey="Gargalidis Moudanos, C" sort="Gargalidis Moudanos, C" uniqKey="Gargalidis Moudanos C" first="C." last="Gargalidis-Moudanos">C. Gargalidis-Moudanos</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM U388, Institut Louis Bugnard, CHU Rangueil</s1>
<s2>31054, Toulouse</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>INSERM U289, CHU Pitié-Salpetrière, 47 Boulevard de l'hôpital</s1>
<s2>75013, Paris</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pizzinat, N" sort="Pizzinat, N" uniqKey="Pizzinat N" first="N." last="Pizzinat">N. Pizzinat</name>
</author>
<author><name sortKey="Javoy Agid, F" sort="Javoy Agid, F" uniqKey="Javoy Agid F" first="F." last="Javoy-Agid">F. Javoy-Agid</name>
</author>
<author><name sortKey="Remaury, A" sort="Remaury, A" uniqKey="Remaury A" first="A." last="Remaury">A. Remaury</name>
</author>
<author><name sortKey="Parini, A" sort="Parini, A" uniqKey="Parini A" first="A." last="Parini">A. Parini</name>
</author>
</analytic>
<series><title level="j" type="main">Neurochemistry international</title>
<title level="j" type="abbreviated">Neurochem. int.</title>
<idno type="ISSN">0197-0186</idno>
<imprint><date when="1997">1997</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurochemistry international</title>
<title level="j" type="abbreviated">Neurochem. int.</title>
<idno type="ISSN">0197-0186</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amine oxidase (flavin-containing)</term>
<term>Binding site</term>
<term>Brain (vertebrata)</term>
<term>Cerebral cortex</term>
<term>Enzymatic activity</term>
<term>Human</term>
<term>Imidazoline I2 receptor</term>
<term>Imidazoline receptor</term>
<term>Parkinson disease</term>
<term>Putamen</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Encéphale</term>
<term>Récepteur imidazoline</term>
<term>Site fixation</term>
<term>Amine oxidase (flavin-containing)</term>
<term>Activité enzymatique</term>
<term>Putamen</term>
<term>Cortex cérébral</term>
<term>Parkinson maladie</term>
<term>Homme</term>
<term>Récepteur imidazoline I2</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">I<sub>2</sub>
-imidazoline binding site (I<sub>2</sub>
BS) has been identified with a regulatory site located on a subpopulation of monoamine oxidase (MAO)-A and -B. Previous studies showed a modification of MAO and I<sub>2</sub>
BS in the elderly and in neurodegenerative processes such as Alzheimer's disease. In the present study. we studied the potential modification of I<sub>2</sub>
 binding sites and monoamine oxidases in Parkinson's disease. Putamen and cerebral cortex were collected from 17 normal subjects (79±12 yr) and 16 patients (76 ± 9 yr) affected by Parkinson's disease. In mitochondrial preparations, radioligand binding studies with [<sup>3</sup>
H]idazoxan showed that putamen and frontal cortex express equivalent amount of I<sub>2</sub>
BS. The density and affinity of I<sub>2</sub>
BS were similar in normal subjects (putamen : B<sub>max</sub>
 = 207 ± 58 fmol/mg of protein, K<sub>d</sub>
 = 10.1 ± 3.4 nM; cerebral cortex: B<sub>max</sub>
 = 193 ± 54 fmol/mg of protein. K<sub>d</sub>
=12.8±6.8 nM) and Parkinson's disease patients (putamen: B<sub>max</sub>
 = 193 ± 60 fmol/mg of proteins K<sub>d</sub>
 = 9.8 ± 4.6 nM: cerebral cortex: B<sub>max</sub>
 = 199 ± 49 fmol/mg of protein, K<sub>d</sub>
 = 15.9 ± 8.1 nM). The activity of total monoamine oxidase and monoamine oxidase B, measured by [<sup>14</sup>
C]tyramine and ['4C]phenylethylamine oxidations respectively, were higher in putamen than in cerebral cortex. No differences have been detected in the enzyme activity between normal and pathological subjects. These data suggest that, although MAO and I<sub>2</sub>
BS may play a role in the development of Parkinson's disease, they are not altered in the chronic phase of this disease.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0197-0186</s0>
</fA01>
<fA02 i1="01"><s0>NEUIDS</s0>
</fA02>
<fA03 i2="1"><s0>Neurochem. int.</s0>
</fA03>
<fA05><s2>30</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>I<sub>2</sub>
-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Imidazoline receptors</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>GARGALIDIS-MOUDANOS (C.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>PIZZINAT (N.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>JAVOY-AGID (F.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>REMAURY (A.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>PARINI (A.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>BOUSQUET (P.)</s1>
<s9>présent.</s9>
</fA12>
<fA14 i1="01"><s1>INSERM U388, Institut Louis Bugnard, CHU Rangueil</s1>
<s2>31054, Toulouse</s2>
<s3>FRA</s3>
</fA14>
<fA14 i1="02"><s1>INSERM U289, CHU Pitié-Salpetrière, 47 Boulevard de l'hôpital</s1>
<s2>75013, Paris</s2>
<s3>FRA</s3>
</fA14>
<fA15 i1="01"><s1>Laboratoire de Pharmacologie Cardiovasculaire et Rénale, CNRS ERS 109, Faculté de Médecine, Université Louis Pasteur, 11, rue Humann</s1>
<s2>67000 Strasbourg</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA20><s1>31-36</s1>
</fA20>
<fA21><s1>1997</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18809</s2>
<s5>354000062829180050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1997 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>30 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>97-0163497</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neurochemistry international</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>I<sub>2</sub>
-imidazoline binding site (I<sub>2</sub>
BS) has been identified with a regulatory site located on a subpopulation of monoamine oxidase (MAO)-A and -B. Previous studies showed a modification of MAO and I<sub>2</sub>
BS in the elderly and in neurodegenerative processes such as Alzheimer's disease. In the present study. we studied the potential modification of I<sub>2</sub>
 binding sites and monoamine oxidases in Parkinson's disease. Putamen and cerebral cortex were collected from 17 normal subjects (79±12 yr) and 16 patients (76 ± 9 yr) affected by Parkinson's disease. In mitochondrial preparations, radioligand binding studies with [<sup>3</sup>
H]idazoxan showed that putamen and frontal cortex express equivalent amount of I<sub>2</sub>
BS. The density and affinity of I<sub>2</sub>
BS were similar in normal subjects (putamen : B<sub>max</sub>
 = 207 ± 58 fmol/mg of protein, K<sub>d</sub>
 = 10.1 ± 3.4 nM; cerebral cortex: B<sub>max</sub>
 = 193 ± 54 fmol/mg of protein. K<sub>d</sub>
=12.8±6.8 nM) and Parkinson's disease patients (putamen: B<sub>max</sub>
 = 193 ± 60 fmol/mg of proteins K<sub>d</sub>
 = 9.8 ± 4.6 nM: cerebral cortex: B<sub>max</sub>
 = 199 ± 49 fmol/mg of protein, K<sub>d</sub>
 = 15.9 ± 8.1 nM). The activity of total monoamine oxidase and monoamine oxidase B, measured by [<sup>14</sup>
C]tyramine and ['4C]phenylethylamine oxidations respectively, were higher in putamen than in cerebral cortex. No differences have been detected in the enzyme activity between normal and pathological subjects. These data suggest that, although MAO and I<sub>2</sub>
BS may play a role in the development of Parkinson's disease, they are not altered in the chronic phase of this disease.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Récepteur imidazoline</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Imidazoline receptor</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Receptor imidazolina</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Site fixation</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Binding site</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sitio fijación</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Amine oxidase (flavin-containing)</s0>
<s2>FE</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Amine oxidase (flavin-containing)</s0>
<s2>FE</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Amine oxidase (flavin-containing)</s0>
<s2>FE</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Activité enzymatique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Enzymatic activity</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Actividad enzimática</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Putamen</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Putamen</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Putamen</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Cortex cérébral</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Cerebral cortex</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Corteza cerebral</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>54</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>54</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>54</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Récepteur imidazoline I2</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Imidazoline I2 receptor</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>45</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>45</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>46</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>46</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>46</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>47</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>47</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>47</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>48</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>48</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>48</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>49</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>49</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>49</s5>
</fC07>
<fN21><s1>076</s1>
</fN21>
</pA>
</standard>
</inist>
<affiliations><list><country><li>France</li>
</country>
<region><li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
<li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
<li>Toulouse</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Javoy Agid, F" sort="Javoy Agid, F" uniqKey="Javoy Agid F" first="F." last="Javoy-Agid">F. Javoy-Agid</name>
<name sortKey="Parini, A" sort="Parini, A" uniqKey="Parini A" first="A." last="Parini">A. Parini</name>
<name sortKey="Pizzinat, N" sort="Pizzinat, N" uniqKey="Pizzinat N" first="N." last="Pizzinat">N. Pizzinat</name>
<name sortKey="Remaury, A" sort="Remaury, A" uniqKey="Remaury A" first="A." last="Remaury">A. Remaury</name>
</noCountry>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Gargalidis Moudanos, C" sort="Gargalidis Moudanos, C" uniqKey="Gargalidis Moudanos C" first="C." last="Gargalidis-Moudanos">C. Gargalidis-Moudanos</name>
</region>
<name sortKey="Gargalidis Moudanos, C" sort="Gargalidis Moudanos, C" uniqKey="Gargalidis Moudanos C" first="C." last="Gargalidis-Moudanos">C. Gargalidis-Moudanos</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001573 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 001573 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:97-0163497
   |texte=   I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease

I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri